Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P12259
UPID:
FA5_HUMAN
Alternative names:
Activated protein C cofactor; Proaccelerin, labile factor
Alternative UPACC:
P12259; A8K6E8; Q14285; Q2EHR5; Q5R346; Q5R347; Q6UPU6; Q8WWQ6
Background:
Coagulation factor V, also known as Proaccelerin or Activated protein C cofactor, plays a pivotal role in hemostasis. It acts as an essential cofactor for the prothrombinase activity of factor Xa, leading to the conversion of prothrombin to thrombin. This process is central to the blood coagulation cascade, ensuring proper clot formation.
Therapeutic significance:
Factor V deficiency, Thrombophilia due to activated protein C resistance, Budd-Chiari syndrome, Ischemic stroke, and recurrent Pregnancy loss are all linked to genetic variants affecting Factor V. Understanding its role could lead to targeted therapies for these conditions, highlighting its importance in vascular health and disease.